Abstract:Background: The high comorbidity and mutually reinforcing relation between depression and cardiovascular disease have raised concerns about the cardiovascular risk of antidepressants. To gain a better understanding of this correlation, we performed a comprehensive evaluation regarding the types and degrees of cardiovascular adverse events (AEs) associated with 37 commonly prescribed antidepressants. Methods: AE reports from January 2004 to December 2023 were retrieved from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was performed to identify antidepressant-related cardiovascular signals using the reporting odds ratio, proportional reporting ratio, and information component. Influencing factors of cardiovascular death, including age, sex, antidepressant choice, and concomitant medication, were explored. The underlying mechanisms of antidepressant-associated cardiovascular risk related to neurotransmitter transporters/receptors were further explored. Results: The use of antidepressants was associated with eight categories of Standardized MedDRA Queries of cardiovascular events. Different antidepressants exerted varying types and degrees of cardiovascular risks along with contributions to death in reports with cardiovascular AEs. Among them, monoamine oxidase inhibitors had the highest risk of developing six cardiovascular event categories: torsades de pointes (TdP)/QT prolongation, hypertension, cardiac arrhythmias, cardiomyopathy, pulmonary hypertension, and ischaemic heart disease. Age, male and the use of 24 types of antidepressants and concomitant medications were positively correlated with death in cardiovascular AEs. The highest risk associated with antidepressants was found in amoxapine (OR = 5.00 [2.13, 11.75], P < 0.001), followed by moclobemide (OR = 3.66 [1.85, 7.24], P < 0.001). Correlation analysis indicated the occurrence of antidepressant-related TdP/QT prolongation, hypertension and cardiomyopathy was associated with the binding and uptake inhibition of dopamine and norepinephrine transporters as well as their selectivity over serotonin transporters. Conclusion: The retrospective analysis revealed that cardiovascular AEs were connected with antidepressant use, and the binding/uptake inhibitory potency and selectivity of neurotransmitters of antidepressants played an important role, providing a preliminary basis for further in-depth study of antidepressant-related cardiovascular toxicity. However, as an exploratory study, prospective studies are needed to validate our findings in the future.

Retrospective analysis of cardiac adverse reactions induced by domperidone

Association Between Polymorphism of Dopamine D2 Receptor Genes and Therapeutic Effect of Domperidone in Functional Dyspepsia.

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Cardiac Arrhythmias during Cytotoxic Chemotherapy: Role of Domperidone

Systematic Review of Domperidone in Clinical Practice

Clinical efficacy observation of Amiodarone and Metoprolol on elderly paients with coronary heart disease by cardiac arrhythmias

Effect of relative bioavailability of domperidone maleate combined with antacids in healthy volunteers

Four-Way Crossover Phase 1 Thorough QT Study to Assess Cardiac Safety of Domperidone and Consideration for Design and Conduct of QT/QTc Study in China

Research progress on adverse drug reaction of arrhythmia induced by azithromycin

Carbapenem Antibacterial Drugs Induced Adverse Drug Reaction

Treatment of functional dyspepsia in Chinese adult patients with domperidone: A multicenter, randomized, double-blind, placebo-controlled pilot study

ADRs monitoring and analysis of cardiovascular drugs

Pharmacokinetics of Domperidone Tablets in Chinese Healthy Volunteers

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

Incidence of Cardiac Adverse Events of Cisapride:a Systematic Review and Meta-analysis

Retrospective Analysis of Adverse Reactions of Indapamide

Exploring the correlation between cardiovascular adverse events and antidepressant use: A retrospective pharmacovigilance analysis based on the FDA Adverse Event Reporting System database

Analysis of Withdrawn Drugs Because of Cardiovascular Adverse Reactions

ADR Induced by Selective Serotonin Reuptake Inhibitors:Literature Analysis

Hyperprolactinemia in Functional Dyspepsia: The Entangled Domperidone Link

Safety Evaluation and Risk Management of Omeprazole